Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance)

Authors:

Abstract
Achievement of complete remission is essential for long-term survival of acute myeloid leukemia patients. We evaluated the prognostic significance of cytogenetics at complete remission in 258 adults with de novo acute myeloid leukemia and abnormal pretreatment karyotypes, treated on Cancer and Leukemia Group B front-line studies, with cytogenetic data at onset of morphologic complete remission. Thirty-two patients had abnormal karyotypes at time of initial complete remission (28 had ≥1 abnormalities seen pretreatment, and four acute myeloid leukemia-related abnormalities not detected pretreatment); 226 patients had normal remission karyotypes. Patients with abnormal remission karyotypes were older (P<0.001), had lower pretreatment white blood counts (P=0.002) and blood blast percentages (P=0.004), were less often classified as Favorable and more often as Adverse among European LeukemiaNet Genetic Groups (P<0.001), and had shorter disease-free (P<0.001; median, 0.6 versus 0.9 years) and overall survival (P<0.001; median, 1.2 versus 2.2 years) than patients with normal remission karyotypes. Sixteen patients with normal remission karyotypes also harbored nonclonal abnormalities unrelated to pretreatment karyotypes. They had shorter overall survival than 210 patients with only normal metaphases (P=0.04). Forty-eight patients with any chromosome abnormality at complete remission, clonal or nonclonal, had worse disease-free (P<0.001; median, 0.6 versus 1.0 years) and overall survival (P<0.001; median, 1.2 versus 2.5 years) than 210 patients with exclusively normal metaphases. In multivariable analyses, the presence of any remission abnormality associated with shorter disease-free (P=0.03) and overall survival (P=0.01), after adjustment for age. We conclude that detection of any abnormality at complete remission is an adverse prognostic factor. ClinicalTrials.gov: [NCT00048958][1]. [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00048958&atom=%2Fhaematol%2Fearly%2F2016%2F07%2F22%2Fhaematol.2016.149542.atom

This publication has 40 references indexed in Scilit: